

TNF ORDER

FAX: 800-987-6552 Phone: 877-283-8679

| PATIENT INFORM | ATION | | | | | | | | |
|---|--|--|--------------------------|--|-----------|---------------------|---------------------|-------------------------------|--|
| Patient Name: | | | | Ship to: Home Office | | | DOB: | | |
| Home Address: | | | | City: | | | State: | Zip: | |
| Home Phone: | | | | Height: | Weight: | | Gender: Mal | e Female | |
| Cell Phone: | | | | Email Address: | | | | | |
| INSURANCE INFORMATION (or attach copy of cards) | | | | | | | | | |
| Primary Insurance Co: Policy Hold | | | der: | Relationship | | Policy#: | Group#: | | |
| Secondary Insurance: Policy Hol | | | der: | Relationship | | Policy#: | Group#: | | |
| CLINICAL INFORMATION (fax all pertinent | | | clini | cal and lab inf | ormation) | | | | |
| Diagnosis (ICD-10): Date of Diagnosis: List of Failed Therapies: | | | | | | | | | |
| Has patient completed ind | uction/loading d | oses? Yes | Yes No Date of last infu | | | on: Date of next in | | nfusion: Access:PIV PICC PORT | |
| Negative TB Test: Yes No Previously vaccinated against Hepatitis B or Negative HBsAg? Yes No Recent liver function tests on file: Yes No | | | | | | | | | |
| List additional comorbidities: Allergies: | | | | | | | | | |
| PRESCRIPTION INFORMATION (or attach a copy of the prescription) | | | | | | | | | |
| TNF - Inhibitor Brand | Remicade | (infliximab) | Inflect | ra (infliximab) | Renflexis | (infliximab) | Simponi Aria | (golumumab) | |
| Induction/Loading Doses | Induction Dose Week # | | | | Dose | | Date received, | if previously administered | |
| | Week # | | | mg OR mg/kg | | | | | |
| | Week # | | | mg OR mg/kg | | | | | |
| | Week # | | | mg OR mg/kg | | | | | |
| Maintenance Dose | Dose: mg OR mg/kg IV once every weeks per manufacturer's guidelines, as tolerated. | | | | | | | | |
| | *Pharmacy will round up to nearest vial size for weight-based dosing. | | | | | | | | |
| | *May adjust infusion schedule +/- 7 days to accommodate nurse and patient scheduling. | | | | | | | | |
| Pre-Medications and Flushing Protocol | Pre-Medications: administered 30 minutes prior to infusion. IV Flushing Protocol: | | | | | | | | |
| | Diphenhydraminemg PO or IV Sodium Chloride 0.9% 5-10 mL pre and pos | | | | | | medication and prn | | |
| | Acetamino | ohen mg PO | | Heparin 10 u/ml Peripheral Line: 3 ml after last NaCl 0.9% flush and | | | | ast NaCl 0.9% flush and prn | |
| | Solu-Medrol mg IV OR Solu-Cortef mg IV Heparin 100 u/ml Central Line: 5ml after last NaCl 0.9% flush and prn | | | | | | | | |
| Refill: PRN x 1 year (OR times) *The quantity and refills for all ancillary medications will match the TNF Inhibitor administration requirements. | | | | | | | | | |
| Anaphylaxis Orders and Medications Provide anaphylaxis kit per pharmacy protocol. | | | | | | | | | |
| Pump and Ancillary Supplies Provide pump and supplies as needed for dilution, administration, and appropriate disposal of infusion material | | | | | | | infusion materials. | | |
| Skilled Nursing Orders and Plan of Treatment | | Provide skilled nursing for home infusion. | | | | | | | |
| | | In-office infusion; no nursing needed. | | | | | | | |
| Administration procedures | | per pharmacy protoc | ol or ma | anufacturer's guideli | nes. | | | | |
| PHYSICIAN INFORMATION | | | | | | | | | |
| | | | | Phone: Fax: | | | | | |
| Office Contact: Email Address: | | | | | | | | | |
| Address: | | | | | | | | | |
| NPI: | | | | | | | | | |
| Prescriber Signature: Date: | | | | | | | | | |
| Your signature authorizes AvevoRx, LLC and their network of pharmacies, Mid-Valley Health System (the "AvevoRx Pharmacies"), to act on your behalf to obtain prior authorization, including | | | | | | | | | |

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 866.442.4679 or by emailing jdent@avevorx.com to obtain instructions as to proper destruction of the transmitted material. Thank you.

appeals and peer to peer reviews, for the prescribed medications. We will also pursue available copay and financial assistance on behalf of your patients.